AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015
Feb 4, 2015
29864_dirs_2015-02-04_2d87dae0-c5bf-4c73-8dfd-ff4a645b73cd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-02-02
Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-02-02 | Common Stock | S | 300 | $108.64 | Disposed | 84200 | Direct |
| 2015-02-02 | Common Stock | S | 788 | $109.80 | Disposed | 83412 | Direct |
| 2015-02-02 | Common Stock | S | 100 | $110.85 | Disposed | 83312 | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $108.64 (range $108.30 to $109.24).
F3: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $109.80 (range $109.42 to $110.37).